31 / 31
Conclusiones
•
Expanded
RAS
analysis should be done at the diagnosis of metastatic
disease to design treatment strategy. Analysis of
BRAF status
is
recomended.
•
Study meta-analysis from published H2H trials supports a potencial
benefit for first line EGFR-inhibitors plus chemotherapy vs
bevacizumab plus chemotherapy with respect to response rate and
overall survival in first line
RAS-w
t mCRC.
•
Existing preclinical and clinical data sugggest that a biological basis exists
for providing
RAS-wt
patients with first-line EGFR inhibitors, followed by
second-line wtih VEGF inhibitors